Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

Koshy George is a true Medicine Man. He knew as a young boy growing up in India that he wanted to make medicine. With his parents encouragement, he earned both a Bachelor and Master degree in Pharmacy ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

<p>Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.</p> ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

<p>Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate risk, and comply with emerging AI regulations.</p> ...